Cipla leaps on Phase III trial for generic version of GSK's Advair Diskus

4 April 2020
cipla-big

Indian drugmaker Cipla Limited (BSE: 500087) saw its shares close up more than 8% at 448.00 rupees on Friday, after it announced the successful completion of Phase III clinical end-point study for fluticasone propionate and salmeterol inhalation powder, a generic version of UK pharma major GlaxoSmithKline’s (LSE: GSK) Advair Diskus.

The product is indicated to treat asthma in patients four years and older as a twice-daily prescription medicine and in long term to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both, for better breathing and fewer flare-ups.

According to IQVIA, Advair Diskus and its generic equivalents had US sales of around $2.9 billion for the 12-month period ending February 2020.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics